Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay
Authors Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ
Received 12 October 2016
Accepted for publication 29 January 2017
Published 6 March 2017 Volume 2017:9 Pages 65—72
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Dr Kenan Onel
Thaddeus S Block,1,2 Tiffany I Murphy,3 Pamela N Munster,4 Dat P Nguyen,1 Frank J Lynch3
1Corcept Therapeutics, Inc, Menlo Park, CA, 2Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 3QualTek Molecular Laboratories, Newtown, PA, 4Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
Background: Glucocorticoid receptor (GR) activity plays a role in many aspects of human physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid tumors. A novel immunohistochemistry (IHC) based assay has been previously developed and validated in order to assess GR immunoreactivity in triple-negative breast cancer. The current study investigates the standardized use of this validated assay to assess GR expression in a broad range of solid tumor malignancies.
Methods: Archived formalin-fixed paraffin-embedded tumor bank samples (n=236) from 20 different solid tumor types were analyzed immunohistochemically. Nuclear staining was reported based on the H-score method using differential intensity scores (0, 1+, 2+, or 3+) with the percent stained (out of at least 100 carcinoma cells) recorded at each intensity.
Results: GR was expressed in all tumor types that had been evaluated. Renal cell carcinoma, sarcoma, cervical cancer, and melanoma were those with the highest mean H‑scores, indicating high levels of GR expression. Colon, endometrial, and gastric cancers had lower GR staining percentages and intensities, resulting in the lowest mean H‑scores.
Conclusion: A validated IHC assay revealed GR immunoreactivity in all solid tumor types studied and allowed for standardized comparison of reactivity among the different malignancies.
Impact: Baseline expression levels of GR may be a useful biomarker when pharmaceutically targeting GR in research or clinical setting.
Keywords: glucocorticoid receptor expression, immunohistochemistry, solid tumors
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]